Dacomitinib

Dacomitinib
Clinical data
Pronunciation	dak" oh mi' ti nib
Trade names	Vizimpro
Other names	PF-00299804
AHFS/Drugs.com	Monograph
MedlinePlus	a618055
License data	US DailyMed: Dacomitinib;
Routes of; administration	By mouth
ATC code	L01EB07 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	80%
Protein binding	98%
Metabolism	CYP2D6, CYP3A4
Metabolites	O-desmethyl-dacomitinib
Elimination half-life	70 hrs
Excretion	79% faeces, 3% urine
Identifiers
	IUPAC name (2E)-N-{4--7-methoxy-6-quinazolinyl}-4-(1-piperidinyl)-2-butenamide;
CAS Number	1110813-31-4 ;
PubChem CID	11511120;
IUPHAR/BPS	7422;
DrugBank	DB11963;
ChemSpider	9685914;
UNII	2XJX250C20;
KEGG	D09883; as salt: D10514;
ChEBI	CHEBI:132268;
ChEMBL	ChEMBL2105719;
PDB ligand	1C9 (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID50149493 ;
Chemical and physical data
Formula	C24H25ClFN5O2
Molar mass	469.95 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4;
	InChI InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+; Key:LVXJQMNHJWSHET-AATRIKPKSA-N;

Dacomitinib, sold under the brand name Vizimpro, is a medication for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.^[3]

Dacomitinib has advanced to several Phase III clinical trials.^[when?] The January 2014 results of the first trials were disappointing, with a failure to meet the study goals.^[4]^[5]^[6] Additional Phase III trials are ongoing^[when?].^[4]

In 2017, results of a trial comparing dacomitinib to gefitinib for NSCLC (driven by mutated EGFR) were announced.^[7]

Dacomitinib was approved for medical use in the United States in September 2018,^[8] in Japan in 2019, and in the European Union in 2019,^[9] for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation.

References

^ "Vizimpro Product information". Health Canada. 25 April 2012. Retrieved 29 May 2022.
^ "Summary Basis of Decision (SBD) for Verzenio". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^ "Dacomitinib". NCI Drug Dictionary. National Cancer Institute, U.S. Department of Health and Human Services.
^ ^a ^b Chustecka Z (27 January 2014). "Dacomitinib Fails in Pretreated Non-small Cell Lung Cancer". Medscape.
^ Taylor P (28 January 2014). "Blow to Pfizer as dacomitinib fails in lung cancer trials". pmlive.com.
^ "Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer". Pfizer Press Release. 27 January 2014.
^ Smith M (6 June 2017). "Dacomitinib Sets PFS Record in Phase III NSCLC Trial". MedPage Today.
^ Shirley M (December 2018). "Dacomitinib: First Global Approval". Drugs. 78 (18): 1947–1953. doi:10.1007/s40265-018-1028-x. PMID 30506139. S2CID 54034570.
^ "Vizimpro EPAR". European Medicines Agency (EMA). 5 June 2019. Retrieved 13 December 2019.

External links

"Dacomitinib". Drug Information Portal. U.S. National Library of Medicine.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=Dacomitinib
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[1] "Vizimpro Product information". Health Canada. 25 April 2012. Retrieved 29 May 2022.

[2] "Summary Basis of Decision (SBD) for Verzenio". Health Canada. 23 October 2014. Retrieved 29 May 2022.

[3] "Dacomitinib". NCI Drug Dictionary. National Cancer Institute, U.S. Department of Health and Human Services.

[medscape-4] Chustecka Z (27 January 2014). "Dacomitinib Fails in Pretreated Non-small Cell Lung Cancer". Medscape.

[5] Taylor P (28 January 2014). "Blow to Pfizer as dacomitinib fails in lung cancer trials". pmlive.com.

[6] "Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer". Pfizer Press Release. 27 January 2014.

[7] Smith M (6 June 2017). "Dacomitinib Sets PFS Record in Phase III NSCLC Trial". MedPage Today.

[8] Shirley M (December 2018). "Dacomitinib: First Global Approval". Drugs. 78 (18): 1947–1953. doi:10.1007/s40265-018-1028-x. PMID 30506139. S2CID 54034570.

[9] "Vizimpro EPAR". European Medicines Agency (EMA). 5 June 2019. Retrieved 13 December 2019.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]